Sofiva Genomics Co.,Ltd. (TPEX:6615)
34.05
-0.30 (-0.87%)
At close: Feb 11, 2026
Sofiva Genomics Revenue
Sofiva Genomics had revenue of 93.41M TWD in the quarter ending September 30, 2025, a decrease of -12.08%. This brings the company's revenue in the last twelve months to 393.48M, down -15.32% year-over-year. In the year 2024, Sofiva Genomics had annual revenue of 453.31M, down -2.89%.
Revenue (ttm)
393.48M
Revenue Growth
-15.32%
P/S Ratio
1.87
Revenue / Employee
n/a
Employees
104
Market Cap
735.26M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 453.31M | -13.49M | -2.89% |
| Dec 31, 2023 | 466.80M | -28.98M | -5.84% |
| Dec 31, 2022 | 495.78M | -12.64M | -2.49% |
| Dec 31, 2021 | 508.42M | 19.55M | 4.00% |
| Dec 31, 2020 | 488.87M | -20.58M | -4.04% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lotus Pharmaceutical | 18.66B |
| PharmaEssentia | 13.82B |
| Radiant Innovation | 413.06M |
| EBM Technologies | 348.42M |
| BioLASCO Taiwan | 277.12M |
| General Biologicals | 251.38M |
| Bioray Biotech | 230.06M |
| PlexBio | 153.06M |